Drug Research
Eisai’s DAYVIGO gets approval in Japan to treat insomnia
Eisai Co., Ltd. announced that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin receptor antagonist DAYVIGO (2.5mg, 5mg, and 10mg tablets, lemborexant) for treatment of insomnia.
DAYVIGO is a dual orexin receptor antagonist...
Drug Research
Eisai Commences Joint Research and Development of Cancer Gene Panel Test With Personal Genome Diagnostics Inc
Eisai Co., Ltd. announced that it has entered into a joint research and development agreement with Personal Genome Diagnostics Inc. for the cancer genetics panel test, and it has initiated the research.
In this joint research and development, Eisai and...
Drug Research
Medigene, IRICoR and Universite de Montreal sign collaboration and exclusive licensing option on novel cancer antigens
Medigene AG , a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, announces that it has entered into a research collaboration on novel cancer antigens for highly specific immunotherapies with the Universite de Montreal (UdeM) and...
Drug Research
Predictive Oncology Acquire Quantitative Medicine and an AI Engine that Facilitates Accelerated Drug Discovery and Development
Predictive Oncology Inc , a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, announces it has signed a letter of intent to acquire Quantitative Medicine.
Dr. Carl Schwartz, president and CEO of Predictive Oncology, believes...
Drug Research
FDF China to be held in June to boost Chinese pharmaceutical enterprises to “go global” and promote the innovation and development of industry
FDF China, collocated with CPhI China, will be held from June 22-24, 2020 at Shanghai New International Expo Centre (SNIEC). More and more formulation enterprises need to implement strategic layout to step up cooperation in innovation and facilitate the...
Drug Research
Discover the Latest Information and Seize Market Opportunities in the Annual Event of the CRO & CMO Industry
As the pharmaceutical market demands in China continue to grow, China’s pharmaceutical policies become gradually clear, which provides broad space for the development of pharmaceutical enterprises. The CRO & CMO industry, an important part of the R&D industry chain...
Drug Research
IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets
IONTAS, a leader in the discovery and optimisation of fully human antibodies, announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells.
The agreement is to generate and optimise...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read